Backed by OrbiMed, Lilly and now Advantech, China's InventisBio loads up $70M to propel cancer, metabolic pipeline
Almost two years after bagging a $19 million round for its early-stage R&D amid some sweeping reforms in China’s regulatory world, Shanghai-based InventisBio is back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.